Hualan Biological Engineering, Inc.

Hualan Biological Engineering, Inc. is a national high-tech enterprise founded in 1992 and listed on the Shenzhen Stock Exchange in 2004. The company specializes in the production, research and development, and marketing of plasma products, vaccines, and genetic engineering products. Hualan Bio is recognized as one of the largest manufacturers of plasma products and influenza vaccines in China, with a registered capital of RMB 930.0876 million. The company has achieved several significant milestones, including the development of the world's first H1N1 influenza vaccine and the first plasma products to gain GMP certification in China. Hualan Bio's main business lines include a diverse range of plasma products such as Human Albumin, Human Immunoglobulin for Intravenous Injection, and various coagulation factors. The company is noted for having one of the highest comprehensive utilization rates of plasma and offers the most complete specifications of coagulation factor products in China's plasma industry. Additionally, Hualan Bio's subsidiary, Hualan Biological Bacterin Co., Ltd, focuses on vaccine development, with several products already on the market and others in the research phase. Hualan Genetic Engineering Co., Ltd, another subsidiary, is engaged in the development of monoclonal antibody drugs, with multiple clinical trials underway.

Hualan Bio is the first company whose plasma products gain GMP certificate in China. The plasma products of Hualan Bio contain three classifications, albumin, immunoglobulin and coagulation factors, with 11 products of 34 specifications in total. Hualan Bio is one of few domestic plasma products manufacturers that can extract six compositions from plasma, as well as one of the companies owning most complete types of coagualtion factor products in the same industry in China. Currently, the production scale, specifications, market share, production and sales amount of leading products of Hualan are on the top in the same industry in China. Hualan Bio is also one of the largest manufacturer of Influenza Vaccine (Split virion), Inactivated in China now. In June 2009, Hualan Bio developed the first Influenza A (H1N1) Vaccine (Split, Inactivated) in the world and undertook nearly 40% of Chinese reserve tasks, providing strong support for the prevention and control of Influenza A epidemic in China. The shareholding subsidiary of Hualan formally marched into the fields of genic recombination and monoclonal antibody in 2013. At present, a number of clinical trials of multiple monoclonal antibody drugs are being conducted.Therefore, based on plasma products, the company develops product portfolio of diversity to further strengthen the dominant position of plasma products; expands the scale of vaccine industry quickly; and develops recombinant hormone drugs and antibody drugs vigorously; what’s more, Hualan expands strategic cooperation with domestic and foreign competitive enterprises; cultivate new profit growth point; enhance the company's core competitiveness. The large biological industry pattern with the core of plasma products, vaccines, monoclonal antibodies and recombinant drugs is gradually formed; clear development strategy in the future ensures the company's sustained and healthy development. Hualan Bio values the return to investors, and the cumulative cash bonus is 2.031 billion RMB from listing.